Published in Health and Medicine Week, April 27th, 2006
Biovirx has an exclusive worldwide license for RotaShield and is planning global commercialization upon appropriate regulatory approvals. IDT currently has existing vaccine production capacity for RotaShield and has initiated construction of a new manufacturing facility for expanded production of the vaccine. The new facility will be located at the IDT complex in Dessau-Tornau, Germany.
IDT is proud to contribute to the reintroduction of RotaShield. Heinz Hofmann, managing director of IDT, pointed out that the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.